Quick Summary:
In a world where preclinical prediction failure rates are high, causing considerable economic losses to the pharmaceutical industry, the advent of the 'organ on a chip' technology presents a groundbreaking solution. This transformational invention facilitates human physiological environment simulation on a microfluidic system, reducing dependency on animal testing models in drug discovery, and heralding a potential revolution in the medical and pharmaceutical sector.
The 'Organ on a Chip Market, 2022-2035' report offers a comprehensive analysis on adoption patterns and future prospects in this emerging technology. Witnessing an upsurge in investments and R&D activities, coupled with regulatory legislative changes, this report presents an ideal opportunity to learn, analyze and plan for the upcoming wave of change. By considering a wide variety of parameters, from product type and application area to geographical distribution, this report offers invaluable insights for stakeholders looking to stay ahead in a rapidly-evolving industry.
It is a well-known fact that almost 90% of the therapeutic interventions fail in clinical trials, resulting in significant economic losses to the pharmaceutical industry. The lack of effective preclinical prediction of drug responses in humans is one of the various reasons for drug’s failure to get approved. Animal testing for preclinical evaluation of drugs sometimes fails to identify toxicity signs caused by a drug in humans. Moreover, these studies are quite expensive, time-consuming and are associated with several ethical concerns. In order to reform the drug approval process and use non-animal testing models for preclinical evaluations, the US democrats and republicans introduced the FDA Modernization Act in 2021. The U.S. Environmental Protection Agency (EPA) has also declared the termination of the funds granted for the studies on mammals by 2035. As a result, several stakeholders have opted to modernize their conventional testing methods in order to cope up with the increasing limitations associated with animal models. One such innovative technology, 'organ on a chip’ has the potential to transform the drug discovery process by simulating the human physiological and functional environment on a microfluidic system.
The use of such novel testing models in drug discovery and toxicity testing has been steadily increasing. Up till now, several pharmaceutical manufacturers and research institutions have embraced the use of these in vivo like in vitro models; however, a remarkable rise in the adoption rate of these models has been observed since the FDA changed its laws towards putting an end on the animal testing models. The novel organ on a chip models have various advantages over the traditional animal-based models, including fine control over microenvironment, lower cost, lesser time, easy to use and portable. Given the inherent benefits of organ on a chip technology, a number of players have launched their proprietary products in order to expedite preclinical studies of novel drug interventions across a wide array of disease indications. There are several organ on a chip models, including lung-on-chip, liver-on-chip, heart-on-chip, brain-on-chip and multiple organ models, which are being offered by various players. Apart from offering efficient user-friendly organ-on-chip models, some developers also offer customization of these models as per the client requests. It is worth mentioning that various developers have made significant efforts in developing organ on chip technologies, paving the way for new innovations, primarily integrating artificial intelligence driven technology for early detection of pharmaceuticals and toxicity risks, along with detection of unknown mutations. Driven by promising benefits over animal testing, increasing R&D activity and financial support from investors, the organ on a chip market is anticipated to grow at a commendable pace in the mid to long term.
Scope of the Report
The “Organ on a Chip Market, 2022-2035: Focus on Products and Technologies - Distribution by Type of Product (Organ(s) based Models and Disease(s) based Models), Application Area (Cancer Research, Drug Discovery and Toxicity Testing, Stem Cell Research and Tissue Engineering and Regenerative Medicine), Purpose (Research and Therapeutic Production), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of organ-on-chip products and technologies, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.
In addition to other elements, the study includes:
- A general introduction of organ on a chip, including history and development, classification, advantages and limitations and applications and future perspectives of organ on a chip.
- A detailed assessment of the current market landscape of organ-on-chips based on a number of relevant parameters, such as type of offering(s) (chip, plate / system, and technology), type of model (organ(s) based and disease(s) based), status of development (commercialized, developed, and under development), type of technology / platform, number of chips in a plate, material used for construction of chip / plate (polymer, glass and silicon), type of polymer (polydimethylsiloxane, cyclic olefin polymer, cyclic olefin copolymer, elastomer, polycarbonate, polypropylene, polystyrene, polyester, tygon, and styrene TEP), compatible tissue / organ, and application area (cancer research, drug discovery and toxicity testing, stem cell research, and tissue engineering and regenerative medicine). In addition, the chapter provides details on the companies engaged in the development of organ-on-chip products and technologies, along with information on their year of establishment, company size and location of headquarters.
- Elaborate profiles of the key players developing organ-on-chips (which are presently commercialized), which are headquartered in North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, its financial information (if available), organ-on-chip product portfolio, recent developments, and an informed future outlook.
- An in-depth analysis of various patents that have been filed / granted for organ on a chip, till 2022, based on various relevant parameters, such as type of patent, publication year, application year, issuing authorities involved, type of organizations, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes an insightful patent valuation analysis.
- A detailed brand positioning analysis of the key industry players, highlighting the current perceptions regarding their proprietary products by taking into consideration several relevant aspects, such as experience of the manufacturer, number of products and technologies offered, product diversity, and number of patents published.
- A study of the various grants that have been awarded to research institutes engaged in projects related to organ on a chip, between 2017 and 2022, based on parameters, such as year of award, support period, amount awarded, funding institute center, grant type, emerging focus area, type of recipient organization, key regions, and leading recipient organizations.
- An analysis of the partnerships that have been established since 2017, covering various types of partnerships, such as research and development agreements, clinical trial agreements, product development and commercialization agreements, technology integration agreements, and product development and manufacturing agreements of the companies focused on developing organ-on-chip products and technologies.
- An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in start-ups / small companies (with less than 50 employees) and mid-sized companies (with 51-200 employees) that are focused on developing organ on a chip products and technologies.
- A case study on scaffold-free 3D cell culture products, including hanging drop plate, 3D petri dish, and ultra-low attachment plate, featuring a list of more than 60 products that are being used for research and pharmaceutical testing, based on a number of relevant parameters, such as status of development (commercialized and developed, not commercialized), type of system (suspension system, attachment resistant and microfluidic system), type of product (ultra-low attachment plate, plate, hanging drop plate, chips and dish) and material used for fabrication (chemical / polymer based, human based and plant based).
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of organ-on-chip market. Based on multiple parameters, such as overall 3D cell culture market, and share of organ on a chip, we have provided informed estimates of the evolution of the market for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of type of product (organ(s) based models and disease(s) based models), application area (cancer research, drug discovery and toxicity testing, stem cell research and tissue engineering and regenerative medicine), purpose (research and therapeutic production), key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of discussions held with the following individuals (in alphabetical order of company / organization names):
- Pierre Gaudriault, (Chief Business Development Officer, Cherry Biotech)
- Matt Dong-Heon Ha (Chief Executive Officer, EDmicBio)
- Michael Shuler (President, Hesperos)
- Jelena Vukasinovic (Chief Executive Officer, Lena Biosciences)
- Maurizio Aiello (Chief Executive Officer, react4life)
- Michele Zagnoni (Chief Executive Officer, ScreenIn3D)
Key Questions Answered
- Who are the leading players engaged in the development of organ-on-chip products and technologies?
- What are the different application areas where organ on a chip can be used?
- Primarily in which geographical regions, are the organ on a chip developers located?
- How has the intellectual property landscape of organ on a chip, evolved over the years?
- Which partnership models are commonly adopted by stakeholders in the organ on a chip domain?
- What are the investment trends and who are the key investors actively engaged in the research and development of organ on a chip systems?
- How is the current and future opportunity likely to be distributed across key market segments?
Table of Contents
Companies Mentioned
- 180 Degree Capital
- 4Dcell
- abc biopply
- Accelera
- AIM Biotech
- Alexandria Venture Investments
- Altana Investissements
- AlveoliX
- AMSBIO
- ANRI
- Aracari Biosciences
- ARLD
- AstraZeneca
- AxoSim
- AXT
- Bpifrance
- Bayer
- Beijing Da Oak Technology
- Beijing Daxiang Technology
- Benson Capital Partners
- BEOnChip
- BGI Group
- Bi/ond
- Biosigma
- BIOFABICS
- BiomimX
- Barcelona Liver Bioservices (BLB)
- bm?t beteiligungsmanagement thüringen (bm|t)
- Brigham and Women's Hospital
- Businesses Private Angels
- Cedars-Sinai Medical Center
- CELLnTEC
- CellSpring
- Chamber of Commerce Milan Monza Brianza Lodi
- Cherry Biotech
- CIC Place de l'Innovation
- CIENCE
- CITIC Securities
- CN Bio
- Congressionally Directed Medical Research Programs
- Corning Life Sciences
- Coulter IDEApitch
- Cyprotex
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences
- DEFTA Partners
- Digital Healthcare Partners
- Draper
- Dynamic42
- EDmicBio
- Duke University
- Eindhoven University of Technology
- EIT Health
- Emulate
- eNUVIO
- Essential Pharma
- European Union
- Evonik Venture Capital
- faCellitate
- Fennik Life Sciences
- FHNW University
- Fidia Farmaceutici
- Fluigent
- FORWARD.one
- Georgia Research Alliance
- Great Stuff Ventures
- Harvard College
- Harvard University
- HCS Pharma
- Hesperos
- HG Initiative
- Hoxton Ventures
- iiCON
- Imec
- INITIO CELL
- Innospark Ventures
- Innovate UK
- InSCREENeX
- InSphero
- InvivoSciences
- Javelin Biotech
- Jiksak Bioengineering
- Johns Hopkins University
- Kirkstall
- Leiden University Medical Center
- Lena Biosciences
- LifeForce Capital
- Lonza
- Massachusetts Institute of Technology
- MBL International
- MediFuture
- Merck KGaA
- Merieux Equity Partners
- MesoBioTech
- MicroBrain Biotech
- MicroFIT
- Micronit
- MicroOrganoLab
- Microtissues
- MIMETAS
- Minifab
- Mittelständische Beteiligungsgesellschaft
- Morgan Noble
- Nanobiose
- National Cancer Institute
- National Center for Advancing Translational Sciences
- National Institute on Aging
- National Institute of Health
- National Institute of Neurological Disorders and Stroke
- National Science Foundation
- Néovacs
- NetAngels
- NETRI
- NeuroProof
- New York Ventures
- Neuro-Zone
- Nexcelom Bioscience
- National Health Research Institutes (NHRI)
- Nikon
- Nortis
- Ohara Pharmaceutical
- OLS - OMNI Life Science
- OMX Ventures
- OncoBone
- Partnership Fund for New York City
- Pear Bio
- Pensées
- Pfizer
- Philip Morris International
- PreciGenome
- Qureator
- RASA
- React4life
- REVIVO BioSystems
- Roche
- SAICO Biosystems
- Sanofi
- S-BIO
- ScienCell Research Laboratories
- Scottish EDGE
- ScreenIn3D
- SOSV
- Sparkasse Jena-Saale-Holzland
- STEMCELL Technologies
- Suzhou Jiyan Biomedical Technology
- SynVivo
- Tachyon Ventures
- Takeda
- TARA Biosystems
- The Administrators of the Tulane Educational Fund
- The Idea Village
- Thermo Fisher Scientific
- Thuringian Ministry of Economics, Science and Digital Society (TMWWDG)
- TissUse
- Trancos Ventures
- uFluidix
- UNIIQ
- University of California
- University of Central Florida
- University of Luxembourg
- University of Pennsylvania
- University of Pittsburgh
- University of Washington
- University of Washington School of Medicine
- University of Washington School of Pharmacy
- U.S. Food and Drug Administration (USFDA)
- Vanderbilt University
- Visikol
- Wake Forest University Health Sciences
- Wavemaker Partners
- Wyss Institute
- Xona Microfluidics
- Yokogawa
Methodology
LOADING...